### Analysis

The Johnson & Johnson Q2 2008 earnings call revealed a mixed bag of results. The company achieved record sales and earnings growth, driven by strong performance in the consumer and medical devices segments. However, the call also highlighted challenges such as generic competition in the pharmaceutical segment, particularly for Procrit and Risperdal Oral, and a potential slowdown in sales due to economic factors.

Key points:
- **Sales Growth**: The company reported a record $16.5 billion in sales, up 8.7% year-over-year, driven by strong performances in the consumer and medical devices segments.
- **Earnings**: Adjusted net earnings of $3.4 billion were up 9.3% year-over-year, with earnings per share increasing by 12.4%.
- **Pharmaceutical Segment**: The pharmaceutical segment saw a decline in sales due to generic competition and market share losses, particularly for Procrit and Risperdal Oral.
- **Medical Devices**: The medical devices segment grew 5.7% operationally, driven by strong performance in the DePuy franchise, with hip and knee growth being particularly notable.
- **Consumer Segment**: The consumer segment achieved strong growth, driven by successful product launches and increased sales of key brands like Zyrtec and Evolence.
- **Cost Management**: The company highlighted its cost-cutting efforts and the implementation of its cost restructuring program, aiming to achieve annual cost savings of $1.3 to $1.6 billion.
- **Pipeline and Product Launches**: The company reported several new product launches and pipeline developments, including the FDA approval of Ustekinumab for psoriasis and the filing of Golimumab for rheumatoid arthritis.

### Conclusion

While the company reported strong results, the challenges in the pharmaceutical segment and potential economic headwinds suggest a cautious outlook. The stock is likely to face short-term pressure due to tempered guidance and uncertainties around key defense contracts. However, the companyâ€™s strong track record of profitable growth and its continued investment in growth opportunities indicate long-term potential.

**Rating: 0**